在患有三级暴露多发性骨髓瘤的患者中,治疗模式,医疗资源利用和症状负担:基于人口的队列研究
Hira Mian1, Hsien Seow1, Gregory R Pond1
1Department of Oncology, McMaster University, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada.
Clinical lymphoma, myeloma & leukemia
|March 2, 2024
概括
接受后续治疗的三级暴露 (TCE) 复发/耐药多发性骨髓瘤 (MM) 患者表现不佳. 观察到高医疗保健使用率和症状负担,以及低息治疗转诊率,表明需要改进管理策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 现实世界的证据研究研究.
背景情况:
- 多发性骨髓瘤 (MM) 是一种血液性恶性瘤.
- 三级暴露 (TCE) 患者已经耗尽了标准疗法.
- 了解TCE患者的结果对于治疗进步至关重要.
研究的目的:
- 描述治疗模式,结果,医疗利用和复发/耐药TCE多发性骨髓瘤患者的症状负担,这些患者接受后续一线治疗 (LOT).
主要方法:
- 使用加拿大安大略省行政数据库进行的回顾性观察队列研究.
- 对接受后续LOT的TCE患者的分析,捕捉治疗细节,到下一次治疗的时间 (TTNT),整体存活率 (OS),医疗保健利用率,息治疗转诊和患者报告的症状.
主要成果:
- 在16777名MM患者中,1358人 (8%) 患有TCE;489人 (36%) 随后接受了大量治疗.
- 常见的后续治疗包括卡菲尔佐米布/德克萨米和波马利多米德/德克萨米.
- 中位数TTNT为1.7个月,中位数OS为12.8个月. 报告指出,医疗保健的使用率很高 (56%的ED/住院病例) 和症状负担很高. 息治疗转诊率很低 (10%).
结论:
- 这项研究代表了TCE患者最大的现实世界系列之一.
- 接下来接受LOT的TCE多发性骨髓瘤患者的结果很差.
- 这些发现突出了管理这种患者群体的重大未满足需求.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
87
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...